Pancreatic Cancer Research

Clinical trialPhase 2Terminated

Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

A Phase II Trial of Celecoxib in Patients With IPMN

Outcome
Stopped early. Results posted; no analysis attachedLack of funding and personnel to conduct study. (Business decision)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
September 2005
Ended
April 2012
Enrollment
8 participants
Sites
1
Primary outcomes
Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months; Concentration of PGE2 in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months; Concentration of PGEM in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months; Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months
Sponsor type
Academic / other
Results posted
29 February 2016
Last update
29 February 2016

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 29 February 2016
Primary outcome
Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 MonthsIPMN Adenoma-Part 1: Surgical Candidate Baseline: 11800, n = 4IPMN Adenoma-Part 1: Surgery Candidate Surgery: 13300, n = 4IPMN Adenoma-Part 1: Surgical Candidate One Week: 12100, n = 4IPMN Adenoma-Part 1: Surgical Candidate 4 Weeks: 19600, n = 4IPMN Adenoma-Part 1: Surgical Candidate 6 Months: 24000, n = 4IPMN low-Part 2: Surgical Candidate Baseline: 21000, n = 4IPMN low-Part 2: Surgery Candidate Surgery: 13400, n = 4IPMN low-Part 2: Surgical Candidate One Week: 4700, n = 4IPMN low-Part 2: Surgical Candidate 4 Weeks: 36300, n = 4IPMN low-Part 2: Surgical Candidate 6 Months: 16000, n = 4IPMN Invasive-Part 3: Surgical Candidate Baseline: 800, n = 4IPMN Invasive-Part 3: Surgery Candidate Surgery: 30000, n = 4IPMN Invasive-Part 3: Surgical Candidate One Week: 15400, n = 4IPMN Invasive-Part 3: Surgical Candidate 4 Weeks: 24800, n = 4IPMN Invasive-Part 3: Surgical Candidate 6 Months: 3600, n = 4IPMN NOS-Part 4: Surgical Candidate Baseline: 10100, n = 4IPMN NOS-Part 4: Surgery Candidate Surgery: 8700, n = 4IPMN NOS-Part 4: Surgical Candidate One Week: 9500, n = 4IPMN NOS-Part 4: Surgical Candidate 4 Weeks: 40300, n = 4IPMN NOS-Part 4: Surgical Candidate 6 Months: 7500, n = 4Values: pg/mlTime frame: Baseline, surgery, 1 wk, 4 wks, and 6 monthsNo analysis posted for this outcome (outcome 1)
Primary outcome
Concentration of PGE2 in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 MonthsIPMN Adenoma-Part 1: Surgical Candidate Baseline: 60, n = 4IPMN Adenoma-Part 1: Surgery Candidate Surgery: 70, n = 4IPMN Adenoma-Part 1: Surgical Candidate One Week: 70, n = 4IPMN Adenoma-Part 1: Surgical Candidate 4 Weeks: 130, n = 4IPMN Adenoma-Part 1: Surgical Candidate 6 Months: 100, n = 4IPMN low-Part 2: Surgical Candidate Baseline: 170, n = 4IPMN low-Part 2: Surgery Candidate Surgery: 90, n = 4IPMN low-Part 2: Surgical Candidate One Week: 10, n = 4IPMN low-Part 2: Surgical Candidate 4 Weeks: 40, n = 4IPMN low-Part 2: Surgical Candidate 6 Months: 10, n = 4IPMN Invasive-Part 3: Surgical Candidate Baseline: 70, n = 4IPMN Invasive-Part 3: Surgery Candidate Surgery: 30, n = 4IPMN Invasive-Part 3: Surgical Candidate One Week: 60, n = 4IPMN Invasive-Part 3: Surgical Candidate 4 Weeks: 10, n = 4IPMN Invasive-Part 3: Surgical Candidate 6 Months: 70, n = 4IPMN NOS-Part 4: Surgical Candidate Baseline: 100, n = 4IPMN NOS-Part 4: Surgery Candidate Surgery: 140, n = 4IPMN NOS-Part 4: Surgical Candidate One Week: 20, n = 4IPMN NOS-Part 4: Surgical Candidate 4 Weeks: 80, n = 4IPMN NOS-Part 4: Surgical Candidate 6 Months: 30, n = 4Values: pg/mlTime frame: Baseline, surgery, 1 wk, 4 wks, and 6 monthsNo analysis posted for this outcome (outcome 3)
Primary outcome
Concentration of PGEM in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 MonthsIPMN Adenoma-Part 1: Surgical Candidate Baseline: 196, n = 4IPMN Adenoma-Part 1: Surgery Candidate Surgery: 177, n = 4IPMN Adenoma-Part 1: Surgical Candidate One Week: 354, n = 4IPMN Adenoma-Part 1: Surgical Candidate 4 Weeks: 431, n = 4IPMN Adenoma-Part 1: Surgical Candidate 6 Months: 522, n = 4IPMN low-Part 2: Surgical Candidate Baseline: 257, n = 4IPMN low-Part 2: Surgery Candidate Surgery: 201, n = 4IPMN low-Part 2: Surgical Candidate One Week: 153, n = 4IPMN low-Part 2: Surgical Candidate 4 Weeks: 594, n = 4IPMN low-Part 2: Surgical Candidate 6 Months: 366, n = 4IPMN Invasive-Part 3: Surgical Candidate Baseline: 128, n = 4IPMN Invasive-Part 3: Surgery Candidate Surgery: NA, n = 4 (Above the level of detection)IPMN Invasive-Part 3: Surgical Candidate One Week: 850, n = 4IPMN Invasive-Part 3: Surgical Candidate 4 Weeks: 453, n = 4IPMN Invasive-Part 3: Surgical Candidate 6 Months: 184, n = 4IPMN NOS-Part 4: Surgical Candidate Baseline: 131, n = 4IPMN NOS-Part 4: Surgery Candidate Surgery: 100, n = 4IPMN NOS-Part 4: Surgical Candidate One Week: 184, n = 4IPMN NOS-Part 4: Surgical Candidate 4 Weeks: 417, n = 4IPMN NOS-Part 4: Surgical Candidate 6 Months: 88, n = 4Values: pg/mlTime frame: Baseline, surgery, 1 wk, 4 wks, and 6 monthsNo analysis posted for this outcome (outcome 4)
Primary outcome
Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 MonthsIPMN Adenoma-Part 1: Surgical Candidate Baseline: 20, n = 4IPMN Adenoma-Part 1: Surgery Candidate Surgery: 4, n = 4IPMN Adenoma-Part 1: Surgical Candidate One Week: 6.4, n = 4IPMN Adenoma-Part 1: Surgical Candidate 4 Weeks: 5.4, n = 4IPMN Adenoma-Part 1: Surgical Candidate 6 Months: 6.7, n = 4IPMN low-Part 2: Surgical Candidate Baseline: 7, n = 4IPMN low-Part 2: Surgery Candidate Surgery: 4.3, n = 4IPMN low-Part 2: Surgical Candidate One Week: 9.3, n = 4IPMN low-Part 2: Surgical Candidate 4 Weeks: 5.9, n = 4IPMN low-Part 2: Surgical Candidate 6 Months: 8.7, n = 4IPMN Invasive-Part 3: Surgical Candidate Baseline: 2, n = 4IPMN Invasive-Part 3: Surgery Candidate Surgery: 3, n = 4IPMN Invasive-Part 3: Surgical Candidate One Week: 11.8, n = 4IPMN Invasive-Part 3: Surgical Candidate 4 Weeks: 5.1, n = 4IPMN Invasive-Part 3: Surgical Candidate 6 Months: 8.3, n = 4IPMN NOS-Part 4: Surgical Candidate Baseline: 9, n = 4IPMN NOS-Part 4: Surgery Candidate Surgery: 3.4, n = 4IPMN NOS-Part 4: Surgical Candidate One Week: 7.2, n = 4IPMN NOS-Part 4: Surgical Candidate 4 Weeks: 4.3, n = 4IPMN NOS-Part 4: Surgical Candidate 6 Months: 1.8, n = 4Values: pg/mlTime frame: Baseline, surgery, 1 wk, 4 wks, and 6 monthsNo analysis posted for this outcome (outcome 5)
Participants
Surgical Candidate: 5 started, 4 completedMedical Candidate: 0 started, 0 completed
Serious adverse events
Surgical Candidate: 2 of 5Medical Candidate: 0 of 0Participants with at least one serious adverse event, of those at risk, as posted

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.

Detailed description public domain (ClinicalTrials.gov)

Efforts at finding a successful chemotherapy for pancreatic cancer have been disappointing. Some patients are at increased risk of pancreatic cancer or may have pre-malignant pancreatic lesions which predispose them to later pancreatic cancer development. In these individuals, chemopreventative measures may block future development of pancreatic cancer. Human tissue studies, cell culture and animal models of pancreatic cancer strongly suggests that cyclooxygenase-2 (COX-2) may be a successful target for chemoprevention. COX-2 is overexpressed in human pancreatic cancers. Elevated COX-2 expression correlates with progression of premalignant precursors of pancreatic cancer in development models of hamster pancreatic cancer. Human tissue studies confirm increases in COX-2 expression with progression of premalignant precursors called intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasms (PanINs). Moreover, COX-2 inhibitors appear to have chemopreventative efficacy in the PC-1 homograft model of hamster pancreatic cancer. Demographic studies have suggested COX-2 inhibitors may confer protection from pancreatic cancer. We propose to conduct a pilot/phase II trial to determine the chemopreventative effects of the COX-2 inhibitor celecoxib in patients with premalignant pancreatic lesions. Patients registered to the study will take celecoxib twice daily for 6-8 weeks prior to surgery (if patient decides to have surgery for his/her condition). If subject is not a surgical candidate or puts off surgical treatment, subject will take celecoxib for 6 months.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months [Baseline, surgery, 1 wk, 4 wks, and 6 months]. Number, pg/ml. IPMN Adenoma-Part 1: Surgical Candidate Baseline (n=4): 11800; Surgery Candidate Surgery (n=4): 13300; Surgical Candidate One Week (n=4): 12100; Surgical Candidate 4 Weeks (n=4): 19600; Surgical Candidate 6 Months (n=4): 24000. IPMN low-Part 2: Surgical Candidate Baseline (n=4): 21000; Surgery Candidate Surgery (n=4): 13400; Surgical Candidate One Week (n=4): 4700; Surgical Candidate 4 Weeks (n=4): 36300; Surgical Candidate 6 Months (n=4): 16000. IPMN Invasive-Part 3: Surgical Candidate Baseline (n=4): 800; Surgery Candidate Surgery (n=4): 30000; Surgical Candidate One Week (n=4): 15400; Surgical Candidate 4 Weeks (n=4): 24800; Surgical Candidate 6 Months (n=4): 3600. IPMN NOS-Part 4: Surgical Candidate Baseline (n=4): 10100; Surgery Candidate Surgery (n=4): 8700; Surgical Candidate One Week (n=4): 9500; Surgical Candidate 4 Weeks (n=4): 40300; Surgical Candidate 6 Months (n=4): 7500.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Clinical Changes in IPMN Progression. [Baseline, 6 months, 1 year].

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Concentration of PGE2 in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months [Baseline, surgery, 1 wk, 4 wks, and 6 months]. Number, pg/ml. IPMN Adenoma-Part 1: Surgical Candidate Baseline (n=4): 60; Surgery Candidate Surgery (n=4): 70; Surgical Candidate One Week (n=4): 70; Surgical Candidate 4 Weeks (n=4): 130; Surgical Candidate 6 Months (n=4): 100. IPMN low-Part 2: Surgical Candidate Baseline (n=4): 170; Surgery Candidate Surgery (n=4): 90; Surgical Candidate One Week (n=4): 10; Surgical Candidate 4 Weeks (n=4): 40; Surgical Candidate 6 Months (n=4): 10. IPMN Invasive-Part 3: Surgical Candidate Baseline (n=4): 70; Surgery Candidate Surgery (n=4): 30; Surgical Candidate One Week (n=4): 60; Surgical Candidate 4 Weeks (n=4): 10; Surgical Candidate 6 Months (n=4): 70. IPMN NOS-Part 4: Surgical Candidate Baseline (n=4): 100; Surgery Candidate Surgery (n=4): 140; Surgical Candidate One Week (n=4): 20; Surgical Candidate 4 Weeks (n=4): 80; Surgical Candidate 6 Months (n=4): 30.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Concentration of PGEM in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months [Baseline, surgery, 1 wk, 4 wks, and 6 months]. Number, pg/ml. IPMN Adenoma-Part 1: Surgical Candidate Baseline (n=4): 196; Surgery Candidate Surgery (n=4): 177; Surgical Candidate One Week (n=4): 354; Surgical Candidate 4 Weeks (n=4): 431; Surgical Candidate 6 Months (n=4): 522. IPMN low-Part 2: Surgical Candidate Baseline (n=4): 257; Surgery Candidate Surgery (n=4): 201; Surgical Candidate One Week (n=4): 153; Surgical Candidate 4 Weeks (n=4): 594; Surgical Candidate 6 Months (n=4): 366. IPMN Invasive-Part 3: Surgical Candidate Baseline (n=4): 128; Surgery Candidate Surgery (n=4): NA [Above the level of detection]; Surgical Candidate One Week (n=4): 850; Surgical Candidate 4 Weeks (n=4): 453; Surgical Candidate 6 Months (n=4): 184. IPMN NOS-Part 4: Surgical Candidate Baseline (n=4): 131; Surgery Candidate Surgery (n=4): 100; Surgical Candidate One Week (n=4): 184; Surgical Candidate 4 Weeks (n=4): 417; Surgical Candidate 6 Months (n=4): 88.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months [Baseline, surgery, 1 wk, 4 wks, and 6 months]. Number, pg/ml. IPMN Adenoma-Part 1: Surgical Candidate Baseline (n=4): 20; Surgery Candidate Surgery (n=4): 4; Surgical Candidate One Week (n=4): 6.4; Surgical Candidate 4 Weeks (n=4): 5.4; Surgical Candidate 6 Months (n=4): 6.7. IPMN low-Part 2: Surgical Candidate Baseline (n=4): 7; Surgery Candidate Surgery (n=4): 4.3; Surgical Candidate One Week (n=4): 9.3; Surgical Candidate 4 Weeks (n=4): 5.9; Surgical Candidate 6 Months (n=4): 8.7. IPMN Invasive-Part 3: Surgical Candidate Baseline (n=4): 2; Surgery Candidate Surgery (n=4): 3; Surgical Candidate One Week (n=4): 11.8; Surgical Candidate 4 Weeks (n=4): 5.1; Surgical Candidate 6 Months (n=4): 8.3. IPMN NOS-Part 4: Surgical Candidate Baseline (n=4): 9; Surgery Candidate Surgery (n=4): 3.4; Surgical Candidate One Week (n=4): 7.2; Surgical Candidate 4 Weeks (n=4): 4.3; Surgical Candidate 6 Months (n=4): 1.8.